danah expect weak pull guidanc
page full analyst note apr
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research apr
estim
price data apr
rate updat apr
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
busi system aim
continu improv scientif technolog portfolio
seek attract market acquir compani
enter expand within nich acquisit danah
aim acceler core growth acquir compani make
 marketing-rel invest also implement lean
manufactur principl administr cost control boost
oper margin overal appreci compani strateg
move push attract scientif tool market
strong growth prospect sticki recur revenu
sale
compani acquisition-focus strategi contribut
becom player highli fragment
rel sticki life scienc diagnost tool market
year first acquisit space radiomet
recent life scienc diagnost acquisit includ
beckman coulter pall cepheid earli
announc plan acquir fill
gap within biopharmaceut develop
manufactur tool market deal close expect earli
especi appreci attract qualiti
biopharmaceut develop manufactur market
includ strong growth trajectori high margin high
switch cost associ regulatori reproduc
concern end user
also continu prune portfolio busi
compani largest divestitur share publicli trade fortiv
corp distribut directli sharehold
second half compani fulli separ dental
strateg thought sale made sens given on-going
commodif weak demand trend core dental
anoth
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
founder transform real estat organ
industrial-focus manufactur compani seri merger
acquisit divestitur includ fortiv separ
danah focus primarili manufactur scientif instrument
life scienc diagnost
environment appli solut late separ
dental busi initi public offer process also made
plan acquir biopharma busi add life scienc
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
danah expect weak pull guidanc
narrow-moat announc preliminari result
first quarter previou expect
crisi compani gave
detail besid top-lin result first quarter
pull guidanc rest year compani
expect give detail earli may report
could remain light economi pull back around
globe continu see share mildli
specif first quarter revenu growth miss
expect firm gener core revenu
growth versu previou guidanc
manag highlight challeng aros late
quarter especi instrument around
sale non-recurring suspect first-quart
shortfal relat gener uncertainti
probabl caus mani custom delay capit
spend extend delay instrument sale may creat
on-going challeng life science/
diagnost compani econom pullback
manag also highlight strong result cepheid
radiomet pall chemtreat quarter
firm diagnostic-rel strength cepheid particular
probabl relat on-going crisi
suspect firm experienc strong demand flu
panel new rapid test receiv
emerg use approv late march food
forward howev increas sale enough
fulli off-set instrument weak first quarter
weak result non-recurring sale could last
throughout econom downturn
fair valu estim remain per share
valuat assum acquir
earli continu make tuck-in acquisit
averag billion annual
add growth prospect valuat
impli price/adjust earn multipl approxim
time expect earn
forecast averag annual organ growth
around pro forma basi also
includ pend acquisit dental
segment ipo futur unannounc tuck-in acquisit
assum net activ materi add
top-lin growth segment expect
organ growth annual basi life scienc
continu benefit grow demand
trend particularli develop manufactur
biopharmaceut expect addit ge
biopharma boost segment growth trajectori
annual forecast period report
basi factor compound annual growth
diagnost segment next five year rel
high growth cepheid molecular diagnost
constrain
environment appli solut also expect
organ growth annual next five year
demand rel high margin tool remain solid
matur
compani integr higher margin ge biopharma
busi control cost gener project
firm profit rise substanti specif
expect oper margin rise
overal base case scenario incorpor
annual next five year free cash flow rise
similar pace period use weight
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
stall weaker growth new product
margin probabl would rise significantli
assum oper margin reach
assum base case scenario
adjust earn per share free cash flow grow
compound annual basi next five year
life scienc diagnost environmental/appli
solut acquisit activ cut
return invest capit recent year
narrow moat rate recogn attract fundament
qualiti core busi appear like
sustain return capit cost least next
year specif see intang asset switch
cost moat sourc
gener compani offer differenti technolog
protect variou intang asset includ
patent brand copyright trademark
intang asset prevent ident copycat long
period time sinc even slightli differenti technic
featur caus end user prefer one tool
anoth similar tool specif applic
precis scientif end market see intang asset
around differenti technolog
also product chosen due differenti
featur specif applic often abl
layer substanti switch cost-rel advantag
tool enabl essenti oper
client switch competitor technolog could
chang outcom oper would
undesir user product
incorpor process overal
danah revenu stream recur natur
major sale consid captiv mean
custom use anoth supplier want keep
averag cost capit roughli discount
stabl result firm acquisition-focus strategi
bull-cas scenario result per share fair valu
estim scenario incorpor organ growth
driven significantli higher growth assumpt
segment stronger growth higher
margin busi on-going cost control project
oper margin rise
assum base case scenario adjust
earn per share free cash flow grow
compound annual basi next five year
bear-cas scenario result per share fair valu
estim time expect earn scenario
incorpor organ growth
base case scenario compani innov engin
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
use instrument equip least
sale dynam highlight razor/razor blade
model pursu
differenti
technolog howev sustain danah
competit advantag differ product set
believ life scienc segment enjoy lengthiest
sustain competit advantag underli basi
differenti proprieti tool affect
perform accuraci speed variou research
project enabl differenti product featur
creat intang asset inform decis use
tool specif applic begin research
project order remain relev scientist earli
research phase must continu innov
contribut intang asset busi well
howev initi decis made see
particularli sticki busi drug develop
manufactur tool repres half
life scienc segment acquisit
close estim product danah
serv biopharmaceut firm discoveri new
molecul product medicin danah
product chosen end user part product
process molecul begin clinic trial
process client unlik switch supplier
addit molecul success market
revenu stream would like continu product
life cycl discoveri patent expir danah
could gener recur revenu year small
molecul even longer difficult-to-manufactur
biolog bode well sustain
econom profit gener busi rest
segment see narrow moat gener
shorter project howev concern reproduc
custom test result cours research
project creat inertia switch
regulatori
technolog period also academ
earli stage research custom feed stickier busi
drug develop manufactur scientist
train danah product earli career may
apt continu use tool certain applic
career progress
diagnost provid broad set tool
tissue-bas molecular diagnost -- sell
primarili hospit physician offic refer lab
use patient blood urin tissu sampl
econom moat busi deriv mix
intang asset switch cost get diagnost
system place lab initi relat differenti
featur proprietari technolog
contribut intang asset moat sourc
segment howev place regular use see
switch cost advantag diagnost
tool specif displac use establish
diagnost platform challeng competitor sinc
lab hesit disrupt system integr
practic pathologist particularli loyal
influenc diagnost platform even test
loyalti tool make work-lif easier high
autom broad set test option would also
note diagnost segment sale repres highest
percentag recur revenu
environment appli solut also
benefit intang asset switch cost
although think lean heavili intang asset
segment segment
highlight segment rel even split
recur versu non-recur revenu tool
segment appear differenti variou featur
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
includ speed accuraci reproduc result
howev segment product benefit long
use live dedic consum requir
continu use product
break-out sale product line two major brand
hach videojet hach municip custom
purchas water qualiti diagnost tool requir
dedic reagent run relat test also
videojet printer place consum good
manufactur use danah rapidli dri ink print best
date lot code rapidli flow product
line hach videojet busi initi
purchas equip use live roughli five
year life instrument consum sale
typic account time price initi
equip purchas also offer servic
tool segment long-term contract
creat anoth recur revenu stream
equip place sticki busi like
make larg portion segment think
environment appli solut contribut
also investor know compani acquisit
activ strateg attract may constrain
return invest capit includ goodwil
forese futur exampl plan acquir
ge biopharma billion net tax benefit time
ebitda recent sold dental segment
investor initi public offer process
under-valued busi opinion howev
recogn activ attract
particular significantli increas exposur
biopharmaceut develop manufactur
busi one could argu wide moat
characterist neg signific invest capit
paid could keep return invest capit
near capit cost sever year valuat
us could constrain return go forward
 activ continu unab given
import acquisit organ expans
strategi expect remain key capit alloc
prioriti danah on-going activ could
eventu cut current narrow moat see enough
posit attribut underli busi on-going
return maintain rate
overal moat trend remain stabl base underli
fundament trend although differ slightli
segment life scienc think decis
expand reach biopharmaceut develop
manufactur tool acquisit
improv profit overal oper
enhanc moat sourc segment howev
valuat offer pend acquisit temper
view transact somewhat environment
appli solut see stabl trend overal
diagnost busi recogn price trend
especi wake on-going protect access
medicar act pama -relat reimburs cut
center medicar medicaid servic
diagnost test could cut return busi
eventu far seen evid
trend hurt diagnost demand margin
significantli one could argu highli autom
system standard test offer supplier like
could benefit price sensit time howev
keep close eye on-going price dynam
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
focus
acceler core growth margin expans
market initi innov
appear posit growth prospect
orec expans highli valu life scienc
diagnost market requir larg outlay
capit includ goodwil eaten
odanah shift healthcar market creat
less cyclic busi attract market high
entri
face signific competit target
nich must remain dedic on-going
relev
plenti opportun consolid
improv perform variou fragment
odivestitur may alway garner fair return
think dental segment sold rel
low price view neg
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
de-lever
flexibl capit market access import recent
year compani issu debt make signific
acquisit beckman coulter pall
cepheid
manag level acquir ge biopharma
estim gross leverag increas
time end time
transact close pro forma basi compani
willing boost financi leverag make ge
biopharma acquisit put even pressur deal
opinion posit though express
desir maintain
investment-grad statu
de-lever think compani de-lever
expect profit growth activ debt repay
stabl result firm acquisition-focus strategi
underli basi compani scientif technolog
gener predict revenu stream life
scienc demand product larg
influenc health biopharmaceut academ
research develop budget current remain
strong uncorrel econom cycl diagnost
compani sell system relat consum
hospit lab laboratori capit budget
fall prey econom cycl comfort
busi reli recur sale
segment one-tim system sale also on-going
pama-rel reimburs cut may cut
price power diagnost player eventu
far seen evid environment
appli solut segment essenti natur
water qualiti tool custom concentr
rel defens consum packag good
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
beverag industri bode well segment demand
even challeng time remain concern
acquisit strategi expand target
also target market richli valu recent
year eaten return invest capit danah
overpay acquisit may abl gener
econom profit also compani typic use
debt leverag financ deal compani
quickli de-lever debt-fund transact
reason acquisit could eventu harm financi
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
repres date owner name posit common share held report holder issuer
share
fund
share
fund
firm biggest risk relat on-going appetit
acquisit
histor perform
manag align sharehold make danah
acquisition-rel declin return invest capit
reason concern maintain favor view
manag invest decis strateg
perspect focus asset industri
attract characterist combin manag
abil improv oper perform
danah busi system includ lean-manufactur
japanes system continu
improv empow leadership focus
custom need combin enabl
becom major player attract market materi
improv mani acquir busi impair
rare compani support view
manag follow disciplin acquisit strategi
integr process think dental segment
manag separ initi public
offer one area
under-perform compani recent histori
cofound brother mitchel steven rale retain
influenc compani root real estat
firm found refocus
steven rale chairman board
mitchel rale chair board execut committe
brother cumul approxim danah
outstand share thoma joyc join
becam ceo follow mani previou
leadership posit compani recent
water qualiti life scienc diagnost segment
joyc also join rale brother compani
board donald ehrlich lead independ
director board sinc director
elect annual execut compens remain
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
highli variabl signific concentr
equity-bas award align manag
sharehold opinion howev sharehold
note short-term incent payment
cash determin primarili adjust earn per
share free cash flow core revenu growth
metric move long-term incent plan
equiti award roic remain pressur
due valuat paid recent pend
acquisit life scienc diagnost remain
somewhat concern chang manag
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
ge biopharma could add
earn close end quarter
narrow-moat report fourth-quart result
slightli beat capit iq consensu expect
line
expect therefor anticip make
signific chang fair valu estim
continu view share overvalu close jan
roughli time earn expect
includ accret potenti grow
core ep low doubl digit compound annual
next five year
oper turn solid result fourth
quarter fulli separ dental oper
envista await acquisit ge biopharma
still expect first quarter revenu grew
core basi billion slightli
consensu billion diagnost led way
growth period beyond low-single-digit growth
beckman diagnost tough compar key brand
radiomet leica cepheid report double-digit
growth rate life scienc core revenu growth
broad-bas strength expect
segment growth could acceler addit ge
biopharma grew
environment appli solut grew
year year
compar hach due part surfac water regulatori
chang china overal though solid top-lin trend
margin expans translat adjust ep
year year consensu
doubl digit
guidanc roughli line
expect compani anticip core revenu
growth oper
margin expans expect core ep exclud ge
biopharma acquisit low doubl digit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
